Blue Cross NCs Blue Premier program saved 164M in 2022 - FierceHealthcare
| CBI Stock | 36.80 0.80 2.13% |
About 62% of Clal Biotechnology's investor base is looking to short. The analysis of current outlook of investing in Clal Biotechnology Industries suggests that many traders are alarmed regarding Clal Biotechnology's prospects. The current market sentiment, together with Clal Biotechnology's historical and current headlines, can help investors time the market. In addition, many technical investors use Clal Biotechnology stock news signals to limit their universe of possible portfolio assets.
Clal |
Blue Cross NCs Blue Premier program saved 164M in 2022 FierceHealthcare
Read at news.google.com
 |
Clal Biotechnology Fundamental Analysis
We analyze Clal Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clal Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clal Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Clal Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Clal Biotechnology stock to make a market-neutral strategy. Peer analysis of Clal Biotechnology could also be used in its relative valuation, which is a method of valuing Clal Biotechnology by comparing valuation metrics with similar companies.
Peers
Clal Biotechnology Related Equities
| ILDR | Israel Land | 7.58 | ||||
| BEZQ | Bezeq Israeli | 0.75 | ||||
| MVNE | Mivne Real | 0.56 | ||||
| PHTM | Photomyne | 0.07 | ||||
| BRIN | Brainsway | 1.89 |
Complementary Tools for Clal Stock analysis
When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Transaction History View history of all your transactions and understand their impact on performance |